Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

John M. Burke, Enrico De Nigris, Yunfei Wang, Kathleen Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Siyang Leng, Ira Zackon

Blood (2025) 146 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2025-2111

Published: 2025

Journal Articles

Real-world hematologic response and treatment patterns among patients with polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg)

Malcolm Charles, Zhaohui Su, Kathleen Aguilar, Robert Reid, Ira Zackon, Drew Bernstein, Stefanie Cribb, Edward Jefford, Paul Walden, Kyle Downey

Blood (2025) 146 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2025-7342

Published: 2025

Journal Articles

Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting

Ping Shi, Kathleen Aguilar, Zhaohui Su, Lisa Herms, Junxin Shi, Jessica Paulas, Ira Zackon

Blood (2025) 146 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2025-7249

Published: 2025

Journal Articles

Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is)

John M. Burke, Enrico De Nigris, Yunfei Wang, Kathleen Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Diana Chirovsky, Inkyu Kim, Siyang Leng, Ira Zackon

Blood (2025) 146 (Supplement 1): 3888.

https://doi.org/10.1182/blood-2025-3888

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Real-world hematologic response and treatment patterns among patients with polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg)

Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting

Email alerts

ASH Publications

American Society of Hematology

Update search

Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Real-world hematologic response and treatment patterns among patients with polycythemia vera (PV) treated with ropeginterferon alfa-2b (ropeg)

Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only